Inhibitor treatment revealed that USP8 is required for growth of glioblastoma stem cells [111], multiple myeloma cells [112] and gefitinib-resistant non-small cell lung cancer cells [113] and demonstrated the existence of a therapeutic window in comparison with growth inhibition of control cells. This evidence concerns the gene USP8 and plasma cell myeloma.